These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29708942)

  • 1. A bifunctional-biased mu-opioid agonist-neuropeptide FF receptor antagonist as analgesic with improved acute and chronic side effects.
    Drieu la Rochelle A; Guillemyn K; Dumitrascuta M; Martin C; Utard V; Quillet R; Schneider S; Daubeuf F; Willemse T; Mampuys P; Maes BUW; Frossard N; Bihel F; Spetea M; Simonin F; Ballet S
    Pain; 2018 Sep; 159(9):1705-1718. PubMed ID: 29708942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bifunctional Peptidomimetic G Protein-Biased Mu-Opioid Receptor Agonist and Neuropeptide FF Receptor Antagonist KGFF09 Shows Efficacy in Visceral Pain without Rewarding Effects after Subcutaneous Administration in Mice.
    Dumitrascuta M; Martin C; Ballet S; Spetea M
    Molecules; 2022 Dec; 27(24):. PubMed ID: 36557917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multitarget μ-Opioid Receptor Agonists─Neuropeptide FF Receptor Antagonists Induce Potent Antinociception with Reduced Adverse Side Effects.
    De Neve J; Elhabazi K; Gonzalez S; Herby C; Schneider S; Utard V; Fellmann-Clauss R; Petit-Demouliere N; Lecat S; Kremer M; Ces A; Daubeuf F; Martin C; Ballet S; Bihel F; Simonin F
    J Med Chem; 2024 May; 67(9):7603-7619. PubMed ID: 38687204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of two novel branched peptidomimetics containing endomorphin-2 and RF9 pharmacophores: Synthesis and neuropharmacological evaluation.
    Zhang T; Han Z; Shi X; Zhao W; Wang Z; Zhang R; Xu B; Zhang M; Zhang Q; Xiao J; Zhu H; Zheng T; Fang Q
    Bioorg Med Chem; 2019 Feb; 27(4):630-643. PubMed ID: 30626554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications.
    Toll L; Khroyan TV; Polgar WE; Jiang F; Olsen C; Zaveri NT
    J Pharmacol Exp Ther; 2009 Dec; 331(3):954-64. PubMed ID: 19773529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments.
    Elhabazi K; Trigo JM; Mollereau C; Moulédous L; Zajac JM; Bihel F; Schmitt M; Bourguignon JJ; Meziane H; Petit-demoulière B; Bockel F; Maldonado R; Simonin F
    Br J Pharmacol; 2012 Jan; 165(2):424-35. PubMed ID: 21718302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OFP011 Cyclic Peptide as a Multifunctional Agonist for Opioid/Neuropeptide FF Receptors with Improved Blood-Brain Barrier Penetration.
    Zhang M; Xu B; Li N; Zhang R; Zhang Q; Chen D; Rizvi SFA; Xu K; Shi Y; Yu B; Fang Q
    ACS Chem Neurosci; 2022 Nov; 13(21):3078-3092. PubMed ID: 36262082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RF313, an orally bioavailable neuropeptide FF receptor antagonist, opposes effects of RF-amide-related peptide-3 and opioid-induced hyperalgesia in rodents.
    Elhabazi K; Humbert JP; Bertin I; Quillet R; Utard V; Schneider S; Schmitt M; Bourguignon JJ; Laboureyras E; Ben Boujema M; Simonnet G; Ancel C; Simonneaux V; Beltramo M; Bucher B; Sorg T; Meziane H; Schneider E; Petit-Demoulière B; Ilien B; Bihel F; Simonin F
    Neuropharmacology; 2017 May; 118():188-198. PubMed ID: 28288815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrathecal administration of MCRT produced potent antinociception in chronic inflammatory pain models via μ-δ heterodimer with limited side effects.
    Zhao Y; Zhang Z; Gou D; Li P; Yang T; Niu Z; Simon JP; Guan X; Li X; He C; Dong S
    Biomed Pharmacother; 2024 Oct; 179():117389. PubMed ID: 39243426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spinal administration of the multi-functional opioid/neuropeptide FF agonist BN-9 produced potent antinociception without development of tolerance and opioid-induced hyperalgesia.
    Zhang R; Xu B; Zhang Q; Chen D; Zhang M; Zhao G; Xu K; Xiao J; Zhu H; Niu J; Li N; Fang Q
    Eur J Pharmacol; 2020 Aug; 880():173169. PubMed ID: 32416184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRV0109101, a G Protein-Biased Agonist of the
    Koblish M; Carr R; Siuda ER; Rominger DH; Gowen-MacDonald W; Cowan CL; Crombie AL; Violin JD; Lark MW
    J Pharmacol Exp Ther; 2017 Aug; 362(2):254-262. PubMed ID: 28533287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MGM-9 [(E)-methyl 2-(3-ethyl-7a,12a-(epoxyethanoxy)-9-fluoro-1,2,3,4,6,7,12,12b-octahydro-8-methoxyindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate], a derivative of the indole alkaloid mitragynine: a novel dual-acting mu- and kappa-opioid agonist with potent antinociceptive and weak rewarding effects in mice.
    Matsumoto K; Takayama H; Narita M; Nakamura A; Suzuki M; Suzuki T; Murayama T; Wongseripipatana S; Misawa K; Kitajima M; Tashima K; Horie S
    Neuropharmacology; 2008 Aug; 55(2):154-65. PubMed ID: 18550129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracerebroventricular administration of CYX-6, a potent μ-opioid receptor agonist, a δ- and κ-opioid receptor antagonist and a biased ligand at μ, δ & κ-opioid receptors, evokes antinociception with minimal constipation and respiratory depression in rats in contrast to morphine.
    Imam MZ; Kuo A; Ghassabian S; Cai Y; Qin Y; Li T; Smith MT
    Eur J Pharmacol; 2020 Mar; 871():172918. PubMed ID: 31958457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats.
    Austin Zamarripa C; Edwards SR; Qureshi HN; Yi JN; Blough BE; Freeman KB
    Drug Alcohol Depend; 2018 Nov; 192():158-162. PubMed ID: 30261403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
    Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC
    Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analgesic tolerance and cross-tolerance to the bifunctional opioid/neuropeptide FF receptors agonist EN-9 and μ-opioid receptor ligands at the supraspinal level in mice.
    Han Z; Jin G; Tang J; Wang H; Guo D; Zhang J
    Neuropeptides; 2023 Feb; 97():102309. PubMed ID: 36410163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a peptidomimetic antagonist of neuropeptide FF receptors for the prevention of opioid-induced hyperalgesia.
    Bihel F; Humbert JP; Schneider S; Bertin I; Wagner P; Schmitt M; Laboureyras E; Petit-Demoulière B; Schneider E; Mollereau C; Simonnet G; Simonin F; Bourguignon JJ
    ACS Chem Neurosci; 2015 Mar; 6(3):438-45. PubMed ID: 25588572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of an
    Quillet R; Schneider S; Utard V; Drieu la Rochelle A; Elhabazi K; Henningsen JB; Gizzi P; Schmitt M; Kugler V; Simonneaux V; Ilien B; Simonin F; Bihel F
    J Med Chem; 2021 Jun; 64(11):7555-7564. PubMed ID: 34008968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydromorphone efficacy and treatment protocol impact on tolerance and mu-opioid receptor regulation.
    Kumar P; Sunkaraneni S; Sirohi S; Dighe SV; Walker EA; Yoburn BC
    Eur J Pharmacol; 2008 Nov; 597(1-3):39-45. PubMed ID: 18789923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.